Why the study?
Does sublingual captopril improve ST-segment depression and hemodynamics in patients with acute myocardial ischemia treated with nitroglycerin and heparin?
Does sublingual captopril improve ST-segment depression and hemodynamics in patients with acute myocardial ischemia treated with nitroglycerin and heparin?
Sublingual captopril provides additional anti-ischemic and hemodynamic benefits when added to nitroglycerin and heparin in patients with acute myocardial ischemia.
Answers are grounded in this paper and cite their sources.
Supports adjunctive sublingual captopril for acute ischemia on nitroglycerin-heparin; extends ACEI evidence to acute settings in RCT.
Summary : To investigate the anti‐ischemic capability of the angiotensin‐converting enzyme inhibitor captopril, 10 patients with acute myocardial ischemia (angina pectoris >1 h, ST‐segment depression ±0.1 mV, no rise in creatine phosphokinase) received 25 mg captopril sublingually after being treated with an intravenous infusion of nitroglycerin (3 mg/h) and heparin (1200 IU/h) for 1 hour. A control group of 10 patients received placebo instead of captopril. Results showed a decrease of the initial ST‐segment depression from 0.25±0.04 to 0.2±0.03 mV (p>0.01) with nitroglycerin for the captopril group and from 0.26±0.05 to 0.21±0.05 mV (p>0.01) for the control group. An additional decrease to 0.13±0.03 mV (p>0.001) was measured after sublingual captopril, while no significant change was found in the placebo group (0.19±0.04 mV). In both groups, 3 patients had no incidents of angina after 1‐h nitroglycerin infusion. An additional 6 patients resolved their complaints after captopril administration in contrast to only 1 after placebo. Two patients in the placebo group required increased doses of nitroglycerin because of impairment of anginal complaints. Hemodynamic measurements documented a significant drop of pulmonary vascular resistance after a 1‐h infusion of nitroglycerin (–12.9% and –13.1%, respectively, p>0.05), while all other parameters remained unchanged. After additional sublingual administration of captopril, a significant increase in cardiac index (+13.8%, p>0.05) was measured and decreases in diastolic pulmonary and blood pressures (–19.2%, p>0.05 and –14.6%, p>0.01), systemic and pulmonary vascular resistance (–17.7%, p>0.01 and –13.6%, p>0.05), and heart rate pressure product (–8.8%, p>0.05), while no significant changes were measured in the control group. No patient suffered acute myocardial infarction during the study period.
No takes yet. Share an insight, caveat, or question.
Haude et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: